Rabbit polyclonal antibody raised against Bevacizumab. Target gene is VEGFA.
Immunogen:
Bevacizumab.
Host:
Rabbit
Specificity:
The product is specific for Bevacizumab. This antibody serves as an excellent positive control for Bevacizumab immunogenicity (ADA) assays.
Form:
Lyophilized
Preparation Method:
This antibody is produced from sera of a rabbit immunized with Bevacizumab.
Purification:
Antigen affinity purification
Recommend Usage:
ELISA (ELISA detection: 0.05-0.2 ug/mL) (Direct ELISA) Immunogenicity assay The optimal working dilution should be determined by the end user.
Storage Buffer:
Lyophilized from PBS, pH 7.4 (0.02% sodium azide).
Storage Instruction:
Store at -20°C on dry atmosphere, lyophilized antibodies are stable at 1 years. After reconstitution with deionized water (or equivalent) to a final concentration of 0.5 mg/mL, it can be stored for 2-3 weeks at 2-8°C or for up to 12 months at -20°C or below. Aliquot to avoid repeated freezing and thawing.
Note:
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. [provided by RefSeq